A patient with MYCN amplified neuroblastoma who had BRCA1/2 mutation signature exposure had a germline SNV in PALB2, and a somatic missense SNV in HERC2. This PALB2 mutation was classified as a VUS in ClinVar but has been reported in patients with breast and colorectal cancer, and PALB2 mutations confer susceptibility to neuroblastoma35–37. Here, MYCN is linked to neuroblastoma.